Keywords: sepracor, submits, copd, nda, arformoterol, drugmaker, focused
Sepracor submits COPD NDA on arformoterol
Article | 19 December 2005
Sepracor, a US drugmaker focused on respiratory and central nervous system disorders, has submitted a New Drug Application to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
